7th Annual MPN Asia 2024 Takes Place in Osaka, Japan
2024 / 04 / 30
PharmaEssentia continues to promote the MPN therapeutical research and development. On April 6, 2024, PharmaEssentia held the 2024 MPN Asia Conference in Osaka, Japan. Nearly 60 key stakeholders attended the event. Cumulatively, the event has reached over 1100 internal and external stakeholders to date.
Experts from the United States, Taiwan, France, Denmark, Japan, South Korea, mainland China, Taiwan, and Singapore have gathered together this year, sharing the latest clinical experiences, international guidelines, and research findings through conference speeches and poster presentations. This international conference in the Asian region aims to promote the advancement of MPN (Myeloproliferative Neoplasms) globally, facilitate exchange and collaboration among experts, continuously drive the treatment and research of MPNs, and further promote the health and well-being of patients.
We believe that the MPN Asia Annual Conference is not only a multinational professional medical symposium on MPN held annually, but also an important platform for demonstrating corporate social responsibility and sustainable development. Rotating throughout Asia each year, this conference continuously fosters a diverse, open, collaborative, and mutually beneficial MPN community. This approach allows for a deep understanding of the different healthcare systems and medical development needs across countries. It also assists in empowering local development, enhancing the healthcare system efficiency. MPN Asia is increasing the global visibility, establishing a strong and resilient global health system for of Taiwan's pharmaceutical research and development industry. The company is proud of realizing the goal and philosophy of sustainable ESG development by creating more sustainable value.
About PharmaEssentia & Ropeginterferon Alfa-2b
PharmaEssentia continues its efforts to improve access to innovative medications for patients with polycythemia vera (PV). As indicated by the latest NCCN guidelines, the United States currently recommends Ropeginterferon Alfa-2b as the first-line treatment for PV patients at high risk of thrombosis. Additionally, for PV patients at low thrombotic risk who exhibit clinical indications for cytoreductive therapy, the first-line recommendation is also Ropeginterferon Alfa-2b.
